WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-07-20·Latest →

Bristol Myers Squibb (BMY) Stock Analysis

OW

BMY Equity Research — OVERWEIGHT — July 2026

← AMGNCVS →

Rating date

Jul 20, 2026

21 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

73p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · BMY

Here is the analysis of BMY as of the trading week ending July 17, 2026 (latest available data before the July 20 date).

Desk rating

OW

Tactical OW · 12M OW

Horizon

Short to medium term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • Strong structural uptrend. BMY is firmly above both the 50- and 200-day moving averages, with the 50-day acting as dynamic support near $56.50.
  • Momentum is accelerating, not exhausted. The MACD line turned positive in early July and continues to rise. RSI at ~59 indicates no overbought stress yet despite the strong recent rally.
  • Recent breakout is noteworthy. The July 13–17 week saw BMY break through the $60 level for the first time, with consistent volume backing the move.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

BMY Research Note

Full desk note for Jul 20, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

32 min read

WebserviceX · Agentic Research Desk

BMY Equity Research Note

Published Jul 20, 2026 · Desk view OVERWEIGHT · Generated 2026-07-21T15:34:51Z · Maintained by Walter Vijayakumar · Methodology · Track record

BMY Stock Rating Summary

BMY bias

OVERWEIGHT

Horizon

Short to medium term

BMY key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

BMY catalyst watch

Strong structural uptrend. BMY is firmly above both the 50- and 200-day moving averages, with the 50-day acting as dynamic support near $56.50.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 73p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-21T15:52:18.528799+00:00.

5D move

—

2026-07-20 → awaiting

Outcome

Awaiting market data

5D trend

+1.38%

Vol (20D ann.)

+35.11%

vs SPY: +2.33%

Close 60.16 → — (USD, vendor closes)

Batch scorecard · 2026-07-20 · BMY

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace f7fd7473…

No QC issues recorded.